Genmab reports Phase 3 trial shows 50% death‑risk reduction for head‑and‑neck cancer combo
+1 new source since this summary was written
Genmab announced that its Phase 3 LiGeR‑HN1 study of petosemtamab combined with pembrolizumab met both primary endpoints in first‑line PD‑L1‑positive recurrent or metastatic head‑and‑neck squamous cell carcinoma. The trial showed a hazard ratio of 0.50 for overall survival and an odds ratio of 3.17 for tumor response, indicating a 50% lower risk of death versus pembrolizumab alone. Analysts upgraded the stock and raised price targets, while the share price jumped roughly 30% to a new 52‑week high.
Why it matters
Analysts now see a higher upside, with the consensus average price target lifted to $94.89, implying about 62% upside from the current price. The positive data could lead to regulatory submissions and future revenue streams if the drug gains approval.
Key facts
- 1The trial’s overall‑survival hazard ratio was 0.50. investing.com
- 2The objective‑response odds ratio was 3.17. investing.com
- 3The combination reduced the risk of death by 50% compared with pembrolizumab alone. investing.com
- 4Genmab shares rose about 30% to $58.15 after the announcement. rttnews.com
- 5The stock reached a 52‑week high of $57.60 during the session. rttnews.com
- 6Trading volume spiked to 19.66 million shares, versus a three‑month average of about 4.14 million. tipranks.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.